Chimeric Therapeutics Limited (CHMMF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 12.8 Million AUD | -23.4% |
| 2023 | 16.71 Million AUD | 82.21% |
| 2022 | 9.17 Million AUD | -19.35% |
| 2021 | 11.37 Million AUD | 17670.2% |
| 2020 | 64 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 12.8 Million AUD | -23.4% |
| 2024 Q2 | 12.82 Million AUD | 25.84% |
| 2024 Q1 | 10.19 Million AUD | -39.02% |
| 2024 Q4 | 12.8 Million AUD | 0.0% |
| 2023 FY | 16.71 Million AUD | 82.21% |
| 2023 Q4 | 16.71 Million AUD | 13.76% |
| 2023 Q1 | 6.4 Million AUD | -30.14% |
| 2023 Q3 | 14.69 Million AUD | 123.81% |
| 2023 Q2 | 6.56 Million AUD | 2.44% |
| 2022 Q3 | 9.02 Million AUD | -14.97% |
| 2022 Q1 | 8.6 Million AUD | -24.38% |
| 2022 Q2 | 10.6 Million AUD | 23.34% |
| 2022 FY | 9.17 Million AUD | -19.35% |
| 2022 Q4 | 9.17 Million AUD | 1.69% |
| 2021 Q1 | 10.93 Million AUD | 0.0% |
| 2021 FY | 11.37 Million AUD | 17670.2% |
| 2021 Q3 | 7.35 Million AUD | -55.1% |
| 2021 Q4 | 11.37 Million AUD | 54.65% |
| 2021 Q2 | 16.38 Million AUD | 49.85% |
| 2020 FY | 64 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -234.49% |
| CSL Limited | 18.62 Billion USD | 99.931% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 75.981% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -33.616% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2937.016% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 82.334% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 78.305% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -232.425% |
| Mesoblast Limited | 188.44 Million USD | 93.206% |
| Marizyme, Inc. | 26.67 Million USD | 52.005% |
| Genus plc | 485 Million USD | 97.36% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -119.133% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -408.8% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -236.923% |
| ContraFect Corporation | 32.53 Million USD | 60.643% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -546.194% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.93 Million USD | 66.248% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -8.702% |
| MultiCell Technologies, Inc. | 1617.67 USD | -791352.274% |
| Accustem Sciences Inc. | 1.07 Million USD | -1086.307% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 83.462% |
| EV Biologics, Inc. | 2.11 Million USD | -505.327% |
| Q BioMed Inc. | 8.13 Million USD | -57.423% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 84.563% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -148.795% |
| Biomind Labs Inc. | 1.49 Million USD | -754.33% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 30.431% |
| Skye Bioscience, Inc. | 14.07 Million USD | 9.019% |
| SQZ Biotechnologies Company | 50.03 Million USD | 74.414% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -8910.23% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -35.255% |
| Intellipharmaceutics International Inc. | 12 Million USD | -6.614% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -6266.021% |
| Neon Bloom, Inc. | 1.22 Million USD | -944.116% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 94.754% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -536.928% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -122.824% |
| GB Sciences, Inc. | 5.41 Million USD | -136.326% |
| Alpha Cognition Inc. | 7.16 Million USD | -78.695% |
| argenx SE | 444.95 Million USD | 97.123% |
| HST Global, Inc. | 593.59 Thousand USD | -2056.88% |
| Halberd Corporation | 728.71 Thousand USD | -1656.93% |
| Enzolytics Inc. | 365.26 Million USD | 96.495% |
| Resverlogix Corp. | 67.39 Million USD | 81.003% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1426.481% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 82.911% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 89.216% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -646.971% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -41.593% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 48.262% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -792.91% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -7.561% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -249.318% |
| AVAX Technologies, Inc. | 3.99 Million USD | -220.578% |
| ONE Bio Corp. | 27.49 Million USD | 53.436% |
| Zenith Capital Corp. | 27.56 Thousand USD | -46340.154% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.034% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -5264.706% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -242.85% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1780.5% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -372.153% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -916.769% |
| Agentix Corp. | 2.51 Million USD | -409.97% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 3.5 Million USD | -265.294% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -19029.355% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 74.528% |
| BioStem Technologies, Inc. | 15.9 Million USD | 19.501% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2655.135% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -46570.382% |
| LadRx Corporation | 2.2 Million USD | -481.819% |
| Cell Source, Inc. | 15.8 Million USD | 19.002% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -28544.814% |
| Regen BioPharma, Inc. | 5.45 Million USD | -134.591% |
| Regen BioPharma, Inc. | 5.45 Million USD | -134.591% |
| NovAccess Global Inc. | 7.86 Million USD | -62.874% |
| Affymax, Inc. | 8.87 Million USD | -44.325% |
| Itoco Inc. | 1.65 Million USD | -674.466% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -524.064% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -111.656% |
| CytoDyn Inc. | 127.89 Million USD | 89.989% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -30530.125% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -717.369% |
| Qrons Inc. | 1.48 Million USD | -760.01% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -15.914% |
| SYBLEU INC | 681.41 Thousand USD | -1778.903% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1482.985% |
| Rebus Holdings, Inc. | 5.24 Million USD | -144.24% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -109.821% |
| Mobile Lads Corp. | 1.31 Million USD | -874.733% |
| International Stem Cell Corporation | 5.27 Million USD | -142.621% |
| Bioxytran, Inc. | 3.24 Million USD | -294.002% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1945.846% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -177.296% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 68.77% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 42.497% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -532.13% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -133.718% |
| Neutra Corp. | 973.52 Thousand USD | -1215.121% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 55.874% |
| PureTech Health plc | 125.58 Million USD | 89.805% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -240.768% |
| IXICO plc | 1.9 Million USD | -573.743% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 37.634% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 87.609% |
| CSL Limited | 18.62 Billion USD | 99.931% |
| Cellectis S.A. | 249.36 Million USD | 94.866% |